Puma biotech buys licenses for oncology treatments that have gone through testing, and brings them to market. I will hold until the ticker hits my target range (7-8 USD,) reevaluate (using FA and TA, and current market conditions to determine price channel and optimize execution,) and trade out.
$Puma Biotechnology(PBYI.US)$• Puma Biotechnology (NASDAQ:PBYI) announced Wednesday that the U.S. FDA has greenlighted a Phase 2 trial to investigate its oral kinase inhibitor alisertib, in-licensed from Takeda (NYSE:TAK), in patients with breast cancer. • The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy. • ...
Puma Biotechnology's high P/E ratio is alarming due to its falling earnings. Despite investor hopes for a business turnaround, analysts remain skeptical. The high P/E and anticipated future earnings drop make current prices seem unjustifiable unless conditions drastically improve.
$Puma Biotechnology(PBYI.US)$Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer 7 MINUTES AGO, 8:30 AM EST VIA BUSINESSWIRE
Puma Biotechnology's EPS declined last year due to unusual items, which potentially distort earnings depiction. Additionally, margins, forecast growth, and ROI need consideration. Also, note four warning signs for the company.
Puma Biotechnology股票討論區
Small cap biopharma, undervalued
加載中...
News
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• ...
Another inexpensive company
A risky small gamble.
Update
7 MINUTES AGO, 8:30 AM EST
VIA BUSINESSWIRE
Nice!
暫無評論